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REVIEW
Differential effects of glucagon-like 
peptide-1 receptor agonists on heart rate
Martin Lorenz1*, Francesca Lawson2, David Owens3, Denis Raccah4, Christine Roy‑Duval5, Anne Lehmann6, 
Riccardo Perfetti7 and Lawrence Blonde8
Abstract 
While glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) are known to increase heart rate (HR), it is insufficiently 
recognized that the extent varies greatly between the various agonists and is affected by the assessment meth‑
ods employed. Here we review published data from 24‑h time‑averaged HR monitoring in healthy individuals and 
subjects with type 2 diabetes mellitus (T2DM) treated with either short‑acting GLP‑1 RAs, lixisenatide or exenatide, 
or long‑acting GLP‑1 RAs, exenatide LAR, liraglutide, albiglutide, or dulaglutide (N = 1112; active‑treatment arms). HR 
effects observed in two independent head‑to‑head trials of lixisenatide and liraglutide (N = 202; active‑treatment 
arms) are also reviewed. Short‑acting GLP‑1 RAs, exenatide and lixisenatide, are associated with a transient (1–12 h) 
mean placebo‑ and baseline‑adjusted 24‑h HR increase of 1–3 beats per minute (bpm). Conversely, long‑acting GLP‑1 
RAs are associated with more pronounced increases in mean 24‑h HR; the highest seen with liraglutide and albiglu‑
tide at 6–10 bpm compared with dulaglutide and exenatide LAR at 3–4 bpm. For both liraglutide and dulaglutide, 
HR increases were recorded during both the day and at night. In two head‑to‑head comparisons, a small, transient 
mean increase in HR from baseline was observed with lixisenatide; liraglutide induced a substantially greater increase 
that remained significantly elevated over 24 h. The underlying mechanism for increased HR remains to be elucidated; 
however, it could be related to a direct effect at the sinus node and/or stimulation of the sympathetic nervous system, 
with this effect related to the duration of action of the respective GLP‑1 RAs. In conclusion, this review indicates that 
the effects on HR differ within the class of GLP‑1 RAs: short‑acting GLP‑1 RAs are associated with a modest and tran‑
sient HR increase before returning to baseline levels, while some long‑acting GLP‑1 RAs are associated with a more 
pronounced and sustained increase during the day and night. Findings from recently completed trials indicate that 
a GLP‑1 RA‑induced increase in HR, regardless of magnitude, does not present an increased cardiovascular risk for sub‑
jects with T2DM, although a pronounced increase in HR may be associated with adverse clinical outcomes in those 
with advanced heart failure.
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Background
The injectable glucagon-like peptide-1 receptor ago-
nists (GLP-1 RAs) are widely used in the management of 
type 2 diabetes mellitus (T2DM) [1]. These agents pref-
erentially lower fasting and postprandial hyperglycemia 
according to their pharmacokinetic (PK) characteristics, 
while also being associated with body weight loss [1–6]. 
GLP-1 RAs exhibit a broad range of effects on the cardio-
vascular system that are independent of changes in blood 
glucose. The majority of these are cardio-protective, 
including lowering systolic and diastolic blood pressure 
[5, 6] and attenuating hypotension induced by intraduo-
denal glucose infusion [7], lowering plasma cholesterol 
level [5, 8] and ischemia–reperfusion injury [9], and 
delaying the progression of atherosclerotic disease [9]. 
GLP-1 RAs have also been suggested to be nephroprotec-
tive [10], even though conflicting data on renal sodium 
and water handling have been reported [10–12].
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GLP-1 RAs induce an increase in heart rate (HR), 
which, theoretically, represents a safety concern, as this 
is considered to be associated with higher cardiovascu-
lar risk [13, 14]. Initially it was believed that this posi-
tive chronotropic effect was not clinically relevant and 
was of a similar magnitude for all GLP-1 RAs. A meta-
analysis of Phase 3 trials reported HR increases in the 
range of 1–4 beats per minute (bpm) for exenatide twice 
daily (BID), exenatide long-acting release (LAR), and 
liraglutide [15]. In these studies, HR was assessed by 
pulse rate measurements at a single time point. In order 
to allow a more sensitive differentiation of GLP-1 RA-
dependent HR effects, the current manuscript presents 
HR data derived from ECG measurements and ambula-
tory blood pressure monitoring at multiple time points 
over 24 h.
Six injectable GLP-1 RAs are currently approved 
for the treatment of T2DM in Europe and in the USA. 
Exenatide is a synthetic version of exendin-4, a potent 
GLP-1 RA isolated from the venom of the Gila monster, 
and approved for BID administration, with exenatide 
LAR being a microsphere formulation of exendin-4 that 
enables once weekly (QW) administration [3]. Lixisena-
tide is structurally related to exendin-4 (six lysine resi-
dues have been added to the C terminus, and one proline 
in the C-terminal region has been deleted) but can be 
administered once daily (QD). Liraglutide is in close 
structural homology to native GLP-1 and is conjugated 
to a palmitic acid to prolong its half-life for QD admin-
istration [3]. Albiglutide comprises two copies of GLP-1 
fused as tandem repeats to the N terminus of albumin 
[3], while dulaglutide is a recombinant fusion protein 
consisting of two GLP-1 peptides covalently linked to a 
human IgG4-Fc heavy-chain variant [3]. These formu-
lations prolong the PK profile of both of these prepara-
tions to allow QW administration [3]. According to their 
respective PK profiles, exenatide BID and lixisenatide 
can be categorized as short-acting agents (each has a 
half-life of 3–5 h) compared with the long-acting agents 
liraglutide, exenatide LAR, albiglutide, and dulaglutide, 
which have half-lives ranging from 12 h to several days 
[16].
Based on the different molecular structures and PK 
characteristics of the GLP-1 RAs and the presence of 
GLP-1 receptors on the sinoatrial node, differential 
effects on HR may be expected. Therefore, the aim of 
this review of published data is to compare the magni-
tude and duration of the effects on HR induced by vari-
ous GLP-1 RAs, both in healthy individuals and in those 
with T2DM, utilizing individual 24-h HR measurements 
from clinical trials, including head-to-head comparison 
data.
Data search
PubMed searches were performed using relevant terms, 
including ‘GLP-1’, ‘GLP-1 receptor agonists’, ‘Exenatide 
BID’, ‘Lixisenatide’, ‘Liraglutide’, ‘Albiglutide’, ‘Dulaglutide’, 
‘Exenatide LAR’, ‘heart rate’, and ‘pulse rate’. Priority for 
inclusion in this manuscript was awarded to studies that 
measured HR over a full 24-h period by serial ECG moni-
toring or those using ambulatory blood pressure meas-
urements including serial or continuous HR detection. 
Two trials fulfilling these criteria directly compared the 
short-acting GLP-1 RA lixisenatide with the long-acting 
GLP-1 RA liraglutide [17, 18]. Moreover, relevant data 
from product monographs were also reviewed.
Effects of short‑acting GLP‑1 RAs on HR
Exenatide BID
In a QT study using serial ECG monitoring, exenatide 
10 µg QD was found to result in a transient HR increase 
of 10  bpm in 62  healthy individuals 2 h after a single 
injection. The effect faded over time, with HR return-
ing to baseline levels after approximately 10  h (Fig.  1a) 
[19, 20]. The peak HR increase mirrored the PK profile, 
which shows that the maximum plasma concentration of 
exenatide is reached 2 h after injection [20]. In a second 
study in 28 patients with T2DM, the mean 24-h HR was 
assessed after 12 weeks’ treatment with exenatide 10 µg 
BID (5  µg BID initiation dose for 4  weeks followed by 
10 µg BID). HR averaged over 24 h increased by 2 bpm 
with exenatide BID compared with a decrease of 1 bpm 
for placebo (n = 26) at the end of the study period [21].
Lixisenatide
In a QT study, HR data from serial ECG measurements 
in healthy individuals receiving lixisenatide 20 µg QD for 
28 days (N = 68; patients with evaluable data n = 61; dose 
titration: 10 and 15 µg during weeks 1 and 2, respectively; 
20 µg during weeks 3 and 4) demonstrated a maximum 
HR increase of 7.3 bpm 4 h post-dosing [22]. As shown in 
Fig. 1b, the changes in HR were transient and reverted to 
baseline after 12 h (Sanofi, data on file; data available on 
request). The mean 24-h HR increase adjusted for base-
line and placebo values was 1.3 bpm [22].
Effect of long‑acting liraglutide QD on HR
A 24-h time-averaged increase in mean placebo- and 
baseline-adjusted HR of 7–8  bpm was reported follow-
ing liraglutide 1.2 and 1.8  mg QD (titrated in 0.6-mg 
weekly steps) using serial ECG monitoring at the end of 
the second and third weeks (after the seventh and final 
dose) of liraglutide (N  =  51). Notably, the elevation in 
HR persisted through the 24-h measurement period for 
both doses, and was characterized by an initial increase 
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followed by a decline and then a second more persistent 
increase (Fig. 2a) [23].
In a second study [24, 25], the effect of liraglutide on 
HR was investigated by 24-h continuous HR monitoring 
in obese individuals (3 mg n = 32; 1.8 mg n = 30) with-
out diabetes following 5  weeks’ treatment (titrated from 
0.6  mg subcutaneously and increased in increments of 
0.6 mg per week, up to end doses of 1.8 and 3.0 mg). HR 
increased during the day and at nighttime with both doses 
compared with placebo (Fig. 2b), with the overall 24-h HR 
increased by 6–7  bpm. The 3.0-mg dose (approved for 
treatment in obese subjects) was associated with a further 
1-bpm HR increase over 24 h compared with the 1.8-mg 
dose. The HR increases with both liraglutide doses were 
more pronounced during nighttime (7.0–8.9  bpm) com-
pared with those seen during the day (4.3–4.6 bpm).
Similar results were obtained in a third placebo-con-
trolled study of liraglutide 1.8 mg, which also employed 
24-h ambulatory HR monitoring in overweight or obese 
hypertensive subjects with T2DM (n = 17). At 3 weeks’ 
follow-up, HR with liraglutide was significantly elevated 
compared with placebo (n  =  17) for the whole 24-h 
period, day- and nighttime (least squares mean differ-
ences were 5.2, 4.6, and 7.3 bpm, respectively) [26].
Comparison of short‑ vs. long‑acting GLP‑1 RAs 
on HR: lixisenatide vs. liraglutide
The effects on HR for the short-acting RA lixisenatide vs. 
the long-acting GLP-1 agent liraglutide were analyzed 
in two independent head-to-head comparison studies 
[17, 18]. In the first trial, lixisenatide 20 µg QD (n = 46) 
and liraglutide 1.2 (n = 44) and 1.8 mg QD (n = 46) were 
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compared following 8  weeks’ treatment in 142 subjects 
with T2DM not adequately controlled with insulin glar-
gine with or without metformin [17]. Both GLP-1 RAs 
were administered in the morning and the approved 
titration schemes were applied. 24-h HR was assessed 
using standard ambulatory blood pressure monitoring at 
baseline and after 8 weeks (Fig. 3).
Mean (standard error [SE]) increases in 24-h HR from 
baseline were 3.3 (1.3) bpm for lixisenatide 20 µg vs. 9.3 
(1.2) and 9.2 (1.3) bpm for liraglutide 1.2 and 1.8  mg, 
respectively (mean differences vs. lixisenatide were 6.0 
and 5.8 bpm for liraglutide 1.2 and 1.8 mg, respectively; 
p  <  0.0001) [17]. Further analysis (Sanofi, data on file; 
data available on request) revealed a 4-bpm increase for 
lixisenatide vs. an approximate 9-bpm increase for both 
liraglutide 1.2 and 1.8 mg during the daytime. At night-
time, lixisenatide increased HR by 2.2  bpm compared 
with approximately 10  bpm for both liraglutide doses 
(Table  1). None of the HR increases correlated with a 
decrease in either systolic or diastolic blood pressure 
(Fig. 4).
A second head-to-head comparison trial between 
lixisenatide and liraglutide was performed in 60 sub-
jects with T2DM [18]. In this study, a 24-h Holter ECG 
recording was performed at baseline, after the maximum 
daily dose for each drug (lixisenatide 20  µg, liraglutide 
0.9  mg) had been administered for at least 1  week fol-
lowing completion of the up-titration period. In the lix-
isenatide-treated group, a significant increase in HR was 
observed only at 5 h post-dosing, and the mean HR per 
day remained unchanged (69.1 ± 8.6 to 71.7 ± 10.6 bpm; 
p =  0.172; Fig.  5). In contrast, in the liraglutide-treated 
group, the mean daily HR increased significantly from 
baseline at all times (66.5  ±  10.2 to 79.7  ±  10.5  bpm; 
p = 0.00021; Fig. 5).
Effects on HR of the long‑acting QW GLP‑1 RAs: 
exenatide LAR, albiglutide and dulaglutide
Exenatide LAR
A thorough QT study evaluated the effects of steady-state 
therapeutic (253 and 399  pg/ml) and supra-therapeutic 
(627  pg/ml) plasma concentrations of exenatide follow-
ing continuous intravenous infusion of exenatide LAR 
to healthy individuals (N  =  86; patients with evaluable 
data, n = 74) over three 24-h periods, each separated by a 
washout period of at least 5 days [27]. HR was monitored 
continuously throughout each infusion period. At these 
two concentrations of exenatide, the mean HR increased 
by up to 16.8 bpm compared with an increase of 5.5 bpm 
with placebo. In a second QT study, the effect of a QW 
injection of exenatide LAR on HR in 148 subjects with 
T2DM was evaluated after 14 and 30  weeks’ treatment 
[28]. In this study, a mean increase in 24-h HR of 3.6 and 
3.5 bpm was observed at weeks 14 and 30, respectively.
Albiglutide
The effect of albiglutide QW on HR was investigated in 
a study involving ECG measurements in 85 healthy indi-
viduals after 6 weeks’ treatment (albiglutide was admin-
istered at a dose of 30  mg [initiation dose] for 2  weeks 
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followed by 50 mg [optional dose based on individual gly-
cemic response] for 4 weeks) [29]. The placebo-corrected 
increase in mean HR from baseline at the end of the 
study (day 39) was up to 3 and 6–8 bpm for the 30- and 
50-mg dose, respectively.
Dulaglutide
The HR effects of dulaglutide 0.75  mg and 1.5  mg were 
investigated using ambulatory blood pressure and HR 
measurements in 505 subjects with T2DM following 
26 weeks’ treatment [30]. Dulaglutide 0.75 mg (n = 251) 
resulted in a mean increase in 24-h HR of 1.3  bpm, 
whereas a 3.5-bpm increase in HR was observed at the 
end of the study for the 1.5-mg dose (n  =  254). When 
comparing effects during the daytime and at nighttime 
after 26  weeks’ treatment, the HR increase compared 
with placebo was only significant during the nocturnal 
period for the lower dulaglutide 0.75-mg dose. For dula-
glutide 1.5 mg, similar HR increases compared with pla-
cebo were reported during both diurnal and nocturnal 
periods.
Discussion
This review evaluates the effect on HR of six approved 
GLP-1 RAs, categorized into a short-acting sub-class 
with half-lives of 3–5 h (exenatide BID and lixisenatide) 
Table 1 Daytime and nighttime HR changes (bpm)
Daytime and nighttime HR changes (bpm) following 8 weeks’ treatment with lixisenatide vs. liraglutide in subjects with T2DM are shown. Please note that n numbers 
are for the number of patients for whom HR data were available
bpm beats per minute, HR heart rate, LS least squares, SE standard error, T2DM type 2 diabetes mellitus
Daytime Lixisenatide 20 μg (n = 40) Liraglutide 1.2 mg (n = 40) Liraglutide 1.8 mg (n = 41)
At baseline 71.0 69.3 70.0
At week 8 74.7 79.3 79.4
LS mean (SE) change from baseline 3.67 (1.42) 9.41 (1.31) 9.10 (1.38)
LS mean (SE) difference vs. lixisenatide 5.74 (1.23) 5.43 (1.20)
Difference vs. lixisenatide: p value <0.0001 <0.0001
Nighttime Lixisenatide 20 μg (n = 42) Liraglutide 1.2 mg (n = 43) Liraglutide 1.8 mg (n = 44)
At baseline 67.1 65.1 66.2
At Week 8 69.7 75.7 76.7
LS mean (SE) change from baseline 2.20 (1.47) 9.97 (1.37) 10.12 (1.45)
LS mean (SE) difference vs. lixisenatide 7.78 (1.26) 7.92 (1.24)
Difference vs. lixisenatide: p value <0.0001 <0.0001
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and a long-acting sub-class with half-lives ranging from 
12 h to several days (liraglutide, exenatide LAR, albiglu-
tide and dulaglutide) [16].
A recent meta-analysis of Phase 3 trials reported 
increases in HR, based on single time point assessments, 
in the range of 1–4 bpm with both long- and short-act-
ing GLP-1 RAs [15]. However, the present review, which 
relies specifically on 24-h-averaged HR data, demon-
strates that the degree of this positive chronotropic effect 
was underestimated when assessed by single time point 
pulse rate measurements. When evaluated with more 
sensitive and reliable 24-h continuous monitoring and in 
thorough QT studies, two of the long-acting GLP-1 RAs, 
liraglutide and albiglutide, were shown to cause a pro-
nounced increase in the 24-h time-averaged mean HR 
from baseline of up to 6–10  bpm, while for dulaglutide 
and exenatide LAR, the increase in 24-h mean HR was 
3–4  bpm [23, 24, 27–30]. The two short-acting GLP-1 
RAs, exenatide BID and lixisenatide, both caused a maxi-
mum HR increase of 8–10  bpm 2–4  h after injection, 
which returned to baseline levels after approximately 
10–12 h (Sanofi, data on file [available on request [22] ] 
and [19, 20]), with a mean 24-h HR increase of approxi-
mately 1–2 bpm for both preparations.
A limitation of the current review is that it focused 
on indirect comparisons of 24-h continuous monitoring 
studies that differed in terms of study population (e.g., 
obese or not-obese, ambulatory or not-ambulatory), 
study treatment (e.g., continuous intravenous infusion, 
or oral administration) and timing of assessment after 
variable duration of study treatment. To overcome this 
limitation, two independent head-to-head compari-
sons between short-acting lixisenatide and long-acting 
liraglutide in subjects with T2DM were also reviewed. 
These direct comparisons allowed a more sensitive dif-
ferentiation of HR effects, and confirmed that lixisenatide 
induces a significantly smaller increase in mean 24-h HR 
compared with liraglutide (4 vs. 9 bpm; Figs. 3, 5) [17, 18].
It could be hypothesized that there is an association 
between the PK of the various GLP-1 RAs, the duration 
of receptor activation/occupancy and the extent of the 
HR effect. Brief receptor occupancy with short-acting 
GLP-1 RAs could explain the transient effect on HR, 
while prolonged receptor occupancy could explain the 
more pronounced HR effect observed with some long-
acting GLP-1 RAs. Furthermore, the longer half-life 
resulting in receptor activation over 24 h would be in line 
with the increased HR during the diurnal and noctur-
nal periods reported for liraglutide and dulaglutide [24, 
30]. However, this relationship does not account for the 
differences in HR increases within the sub-class of the 
long-acting agents. The differential effects of these mol-
ecules could be explained by differences in their affin-
ity for the GLP-1 receptor, especially variations in their 
binding kinetics, e.g., on/off rates. Furthermore, the dif-
ferences between the agents in terms of the duration of 
their effect may be due to tachyphylaxis and/or receptor 
desensitization.
The underlying mechanism for the increased HR has 
not yet been fully elucidated. It was initially postulated 
to be a compensatory mechanism to the blood pressure 
lowering effect of GLP-1 RAs that was possibly mediated 
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by their vasodilatory effect [9, 31] and/or increased uri-
nary sodium excretion [32]. However, no association 
between HR and blood pressure was observed in the 
head-to-head comparison trial of liraglutide and lixi-
senatide [17] (Fig. 4). It is more likely that increased HR 
results from a direct GLP-1 receptor-mediated effect on 
the endogenous sinoatrial pacemaker node of the heart, 
as GLP-1 receptors are expressed in the human heart 
in myocytes in the sinoatrial node [33]. Such a direct 
GLP-1 mechanism is supported by studies using native 
GLP-1 and exenatide in healthy people and patients with 
T2DM showing that the acute increase of HR was not 
preceded by a decrease in blood pressure, was not asso-
ciated with changes in plasma levels of adrenaline or 
noradrenaline, and was independent of GLP-1 glucoregu-
latory effects [11, 34, 35]. A further possibility is that the 
positive chronotropic effect could be, at least partially, 
mediated by sympathetic nervous system enhancement, 
related to the inhibition of the autonomic nervous sys-
tem [18, 36, 37]. In subjects with T2DM, 24-h Holter 
ECG and power spectrum analysis of HR variability were 
conducted before and after liragutide or lixisenatide 
administration. In the liraglutide group, significant dif-
ferences were observed in the low (0.04–0.15  Hz)/high 
(0.2–0.4  Hz) frequency ratio; however, no changes in 
the low/high frequency ratio were found in the lixisena-
tide group [18]. This mechanism of action would explain 
the more marked increase in HR induced by liraglutide 
in those subjects with T2DM at night when parasympa-
thetic activity is predominant. Diminished parasympa-
thetic modulation of the heart resulting in increased HR 
was also observed in response to intracerebroventricular 
infusion of exendin-4 in mice [36].
A substantial volume of data indicates that an elevated 
HR is independently associated with increased cardiovas-
cular morbidity and mortality in the general population, 
in subjects with cardiovascular diseases, and those with 
diabetes [13, 14, 38, 39]. In the action in diabetes and vas-
cular disease (ADVANCE) trial, a study involving 11,140 
subjects with T2DM who were followed for a median 
duration of 4.4 years, a higher HR was associated with a 
significantly increased risk of all-cause mortality, cardio-
vascular death, and major cardiovascular events (death, 
nonfatal acute myocardial infarction [AMI] or nonfatal 
stroke) [39]. In the same study population, a higher HR 
was also associated with a greater incidence of new-onset 
or progressive nephropathy and retinopathy [38]. It is 
unclear whether a higher HR is directly responsible for 
the increased cardiovascular risk. However, in support 
of a causal relationship, lowering of HR by ivabradine, a 
selective inhibitor of the sinus node I(f ) channel, devoid 
of any activity on blood pressure, cardiac contractility, 
atrioventricular conduction or ventricular repolarization, 
decreased the risk of cardiovascular death or hospitaliza-
tion due to heart failure (HF) in subjects with HF, which 
is a debilitating condition highly sensitive to changes in 
HR [40].
HF is one of the most common complications of dia-
betes, and patients with diabetes are at a higher risk of 
developing HF [41]. Also, diabetes adversely affects the 
outcomes of subjects with HF, substantially decreasing 
their survival rate [42]. Achieving good glycemic con-
trol in subjects with T2DM and HF is difficult, as several 
antihyperglycemic agents have been reported to increase 
the risk of hospitalization due to HF [43–45]. GLP-1 RA 
treatment might be expected to improve HF outcome 
by augmenting glucose uptake by the myocardium, a 
potentially important mechanism in HF as fatty acid 
metabolism is down-regulated, and adenosine triphos-
phate synthesis is more dependent on glucose. However, 
in a recent placebo-controlled crossover study to evalu-
ate the effects of liraglutide in subjects with T2DM and 
coronary artery disease undergoing dobutamine stress 
echocardiography (DSE), liraglutide did not improve 
the systolic function of the left ventricle during DSE or 
patients’ exercise capacity [46]. The National Heart, Lung 
and Blood Institute Heart Failure Clinical Research Net-
work designed the Functional Impact of GLP-1 for Heart 
Failure Treatment (FIGHT) study (NCT01800968) to test 
the hypothesis that liraglutide would improve myocar-
dium bioenergetics leading to post-hospitalization clini-
cal stability in subjects with advanced HF and reduced 
left ventricular ejection fraction, with and without dia-
betes [47]. The study results were published recently [48] 
and indicated that liraglutide did not improve clinical 
stability but was rather associated with a numerical but 
not statistically significant increase in the composite of 
death or HF hospitalization compared with placebo. Sub-
jects who received liraglutide were also reported to have 
a higher incidence of arrhythmia vs. placebo (17 vs. 11%, 
respectively). Similar findings were observed in the Effect 
of LIraglutide on left VEntricular function in chronic 
heart failure patients with and without type 2 diabetes 
(LIVE) study [49, 50]. The trial randomized 241 patients 
with chronic HF with reduced left ventricular ejection 
fraction to receive liraglutide or placebo. After 24 weeks’ 
treatment, there were no significant differences between 
the groups for the primary endpoint of change in left 
ventricular ejection fraction, regardless of whether the 
patients had comorbid diabetes or not. However, patients 
treated with liraglutide suffered numerically more seri-
ous adverse cardiac events than those on placebo (12 vs. 
3, respectively; p = 0.04). It is not known whether these 
adverse clinical outcomes could have been mediated by 
the pronounced and prolonged increase in HR induced 
by liraglutide.
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The results of the Liraglutide Effect and Action in Dia-
betes: Evaluation of Cardiovascular Outcome Results 
(LEADER) trial were published recently [51]. In this ran-
domized trial of more than 9300 subjects with T2DM 
and high cardiovascular risk, liraglutide was seen to 
decrease the incidence of the composite cardiovascular 
primary endpoint (occurrence of death from cardiovas-
cular causes, nonfatal myocardial infarction, or nonfatal 
stroke) compared with placebo (13.0 and 14.9% in the 
liraglutide and placebo group, respectively; hazard ratio 
[HR]: 0.87; 95% confidence interval [CI] 0.78, 0.97). Lira-
glutide was also associated with a decrease in death from 
cardiovascular causes and death from any cause, and did 
not increase the risk of hospitalization due to HF in the 
overall patient population. No analysis was conducted in 
the subgroup of patients with HF at baseline (approxi-
mately 14%) to determine whether treatment with lira-
glutide was associated with any change of severity of HF 
and/or cardiovascular mortality.
The results of the Evaluation of LIXisenatide in Acute 
coronary syndrome (ELIXA) trial, the first cardiovascular 
outcomes trial for the short-acting GLP-1 RA lixisena-
tide, were also published recently [52]. This placebo-con-
trolled study in more than 6000 subjects with T2DM and 
acute coronary syndrome demonstrated the cardiovas-
cular safety of chronic exposure to lixisenatide. Follow-
ing a median follow-up of 2.1 years, the risk of suffering a 
major cardiovascular adverse event (death, nonfatal AMI, 
nonfatal stroke or hospitalization for unstable angina) 
was similar in both the lixisenatide and the placebo arms 
(HR 1.02; 95% CI 0.89, 1.17). Furthermore, lixisena-
tide showed a consistent neutral effect on all individual 
components of the primary and secondary endpoints. 
Importantly, lixisenatide did not increase the risk of hos-
pitalization for HF compared with placebo. The percent-
ages of subjects who were hospitalized for HF were 4.0 
and 4.2% in the lixisenatide and placebo group, respec-
tively (HR 0.96; 95% CI 0.75, 1.23).
While LEADER and ELIXA were similar in terms of 
their overall design, there were some major differences 
between the patient populations enrolled in the two 
studies. Most notably, the patients enrolled in LEADER 
had chronic cardiovascular risk (either a pre-existing 
cardiovascular condition or a high risk for cardiovas-
cular disease), while only those individuals who were 
within 180  days post-acute coronary event and, hence, 
at the highest risk of a further cardiovascular event, were 
included in ELIXA. As a result of the different event rates 
in the two studies, the median durations of follow-up 
were also substantially different (3.8  years in LEADER 
vs. 2.1  years in ELIXA). Reduction of atherosclerosis 
requires long-term treatment [53], hence longer trials are 
better suited to show a reduction in risk of myocardial 
infarction or other atherosclerotic complications of dia-
betes. Furthermore, several key baseline characteristics 
were also different between the two study populations. 
For example, mean ± standard deviation glycated hemo-
globin levels were 8.7 ± 1.5% in LEADER and 7.7 ± 1.3% 
in ELIXA. As these and other differences between ELIXA 
and LEADER may have affected the overall results of the 
two studies, comparisons between them and extrapo-
lations from one study to another should be made with 
caution.
Overall, the findings from these two recently completed 
cardiovascular outcomes trials suggest that the increases 
in HR associated with the short-acting GLP-1 RA, lixi-
senatide, or the long-acting GLP-1 RA, liraglutide, do not 
lead to an increased risk of major adverse cardiac events 
in patients with T2DM and high cardiovascular risk. Car-
diovascular outcomes trials are still ongoing for the other 
GLP-1 RAs (Table 2) and will provide further insight on 
the CV effects of these agents.
Conclusions
In conclusion, this review shows that long-acting GLP-1 
RAs induce a pronounced and prolonged increase in 
24-h mean HR, while short-acting agents lead to a more 
transient increase that reverts to baseline levels within 
a few hours after injection. The underlying mechanisms 
for increased HR remain to be fully elucidated, but may 
be related to a direct GLP-1 receptor effect on myocytes 
in the sinoatrial node of the human heart and/or stimu-
lation of the sympathetic nervous system. According to 
the recently completed ELIXA and LEADER trials, an 
increase in HR, regardless of its magnitude, does not 
appear to increase the cardiovascular risk of individuals 
with T2DM and with (or at high risk of ) cardiovascular 
disease. However, a pronounced increase in HR may be 
associated with adverse clinical outcomes in subjects 
with both T2DM and advanced HF.
Table 2 Ongoing CVOT for GLP‑1 RAs
Data in table derived from ClinicalTrials.gov
CVOT cardiovascular outcome trial, GLP-1 RA glucagon-like peptide-1 receptor 
agonist, QW once weekly
Drug CVOT (ClinicalTrial.gov ID) n Estimated 
completion 
date
Exenatide QW EXSCEL (NCT01144338) 14,000 2018
Dulaglutide REWIND (NCT01394952) 9622 2019
Albiglutide HARMONY outcomes 
(NCT02465515)
9400 2019
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